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Abstract:  Pemphigus is a chronic potentially fatal autoimmune disorder that 
causes blisters and erosions of the skin and oral mucous membrane. Most of 
the cases present oral manifestations as the first clinical sign along with dermal 
lesions. Only 0.5 to 3.2 of cases are reported each year per 1,000,000 population 
with oral manifestations without dermal participation, and is at times difficult 
to diagnose. We report a case of oral pemphigus vulgaris in a 20 year old female 
patient without dermal manifestations treated with oral mini pulse therapy.
Keywords: Autoimmune diseases; blister, pulse therapy; pemphigus.
INTRODUCTION.
Pemphigus is a chronic inflammatory mucocutaneous autoimmune 
disorder, characterized by blisters and erosions of the skin and the 
mucous membrane.1 0.5 to 3.2 cases are reported each year per 1,000,000 
population with oral manifestations without dermal participation. 
Pemphigus is most commonly seen in the 5th and 6th decade of life, and 
rarely seen in children, and has a predominance in females with a male 
to female ratio of 1:2.2,3  Pemphigus Vulgaris (PV), Pemphigus Vegetans, 
Pemphigus Foliaceus, Pemphigus Erythematous, Paraneoplastic Pemphigus 
(PNP) and drug related pemphigus are major variants of pemphigus. 
Eighty percent of cases are encounter correspond to PV, initially affects 
the oral mucosa, without any cutaneous involvement, and can be difficult 
to diagnose.4 Here, we report a case of oral PV in a 20 year old female 
patient without dermal manifestations.  
CASE REPORT.
A 20-year-old female patient reported to the Department of Oral 
Medicine and Radiology of the Mamata Dental College and Hospital with 
the chief complaint of ulcers in the mouth for the past two months. 
History revealed that first she noticed difficult swallowing while eating, 
whose severity had progressively increased. Later, she had noticed ulcers 
in the mouth that bled on brushing and also gave a history of increased 
salivation in the morning. The patient did not report any skin lesions. 
Her medical and family history was noncontributory.
Extra oral examination revealed palpable right and left submandibular 
lymph nodes, which were enlarged, mobile and tender. Intra oral 
examination revealed ulcerative lesions present bilaterally on the buccal 
mucosa along the line of occlusion extending anterio-posteriorly from 
Conflict of interests: The authors declare no 
conflict of interests.
Ethics approval: Ethical approval granted 
by the Research and Ethics committee of 
the Mamata Dental College and Hospital, 
Telangana, India.
Funding: None.
Authors’ contributions: All authors contri-
buted to the work.
Acknowledgements: None.
Cite as: Kumar Reddy KV, Maloth KN, 
Meesala T & Thakur M. Oral Pemphigus 
Treated with Minipulse Therapy. J Oral Res 
2018; 7(9):432-436.
doi:10.17126/joralres.2018.087
Receipt: 07/10/2018 Revised: 10/26/2018
Acceptance:   10/24/2018 Online: 12/17/2018
433ISSN Online 0719-2479 - www.joralres.com © 2018
the retrocommisural areas to the retromolar trigone 
region. The lesions were irregular in shape covered by 
a pseudo-membrane and an erythematous surrounding 
area. Bleeding was evident on palpation. Erosive lesions 
were observed involving the posterior hard plate and soft 
palate. There were diffuse areas of erosions covered by a 
pseudo-membrane at some sites with positive Nikolsky's 
sign. Generalised gingival inflammation with bleeding 
on probing was present. (Figure 1) 
Based on the clinical examination and the patient’s 
history pemphigus was diagnosed, with a differential 
diagnosis of pemphigus vulgaris, mucous membrane 
pemphigoid, bullous lichen planus, paraneoplastic 
pemphigus, chronic ulcerative stomatitis, recurrent 
herpes lesions in immunocompromised patients and 
erythema multiforme. 
Routine baseline investigations such as hematological 
and biochemical investigations were within normal limits. 
Incisional biopsy was performed and histopathological 
examination revealed parakeratinized stratified squamous 
epithelium with intra-epithelial blister formation. Split 
area was covered by a thick area of fibrinous exudate 
consisting of inflammatory cells. Occasional giant cells 
were seen in the split area. (Figure 2) 
Chronic inflammatory cell infiltrate in the sub- 
epithelial and perivascular region was evident. Based 
on the histopathological findings, a final diagnosis of 
pemphigus vulgaris was made. 
The treatment plan comprised of oral prednisolone 
(Wysolone, Pfizer) 30mg/day for four days along with a 
multi-vitamin and topical analgesic. On the first follow-
up, the patient had 50% reduction in symptoms with 
Figure 1. Intra- and Extra-oral signs at presentation.
Figure 2. Histopathology picture shows suprabasilar split with acantholysis of keratinocytes.
A. Ulcerative lesions on right buccal mucosa.  B. Ulcerative lesions on left buccal mucosa. C. Desquamative gingivitis. D. Erosive lesions 
involving hard and soft palate.
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A.  Partial remission of the lesions on right buccal mucosa.  B. Complete remission of the lesions on left buccal mucosa. C. Complete hea-
ling of the desquamative gingivitis.  D.  Complete remission of the lesions on posterior hard plate and soft palate.
Figure 3. Post-treatment follow up after 10 days of treatment, intra oral examination 
showed 70% remission of the lesions.
A.  Remission of the lesions on right buccal mucosa. B. Remission of the lesions on left buccal mucosa.  C. Healing of the desquamative 
gingivitis. D. Remission of the lesions on posterior hard plate and soft palate.
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partial healing of lesions; erythema and inflammation 
in relation to ulcers had reduced. The dose of Wysolone 
was tapered to 20mg/day for the next four days, and 
0.1% triamcinolone acetonide topical ointment was 
also prescribed to the patient. On the second follow-
up, a further 20% reduction in symptoms was noticed 
compared to the first follow-up visit, and a reduction in 
the number of lesions was noted. 
The dose of prednisolone was tapered to 10mg/day for 
4 four days. (Figure 3) On the third follow-up, symptoms 
were completely reduced. The dose of prednisolone was 
further tapered to 5mg/day for the next three days. 
On the final visit, complete regression of lesions were 
noticed. (Figure 4)
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DISCUSSION.
Pemphigus includes a group of potentially fatal 
autoimmune mucocutaneous blistering disorders, 
characterized by acantholysis. The autoantibodies (IgG) 
target desmoglein 3, a transmembrane glycoprotein found 
in the desmosome involved in intercellular adhesion.5 
Most variants of pemphigus are classified as subtypes 
pemphigus vulgaris (PV), pemphigus foliaceus (PF), pemphigus 
erythematosus (PE) and paraneoplastic pemphigus (PNP).5
Clinically, it is most commonly seen in the 5th and 
6th decade of life, and rarely seen in children with a 
predominance in females with a male to female ratio of 
1:2.2,3 70-90% of the cases present oral manifestations 
as the first clinical sign,6 primarily involving the buccal 
mucosa, pharynx and gingiva. The cutaneous part 
involving the chest, face, scalp, upper back, and areas of 
trauma are common sites.7 The present case was consistent 
with the literature except regarding age, which was younger 
in the present case, at 20 years old and with no cutaneous 
involvement. 
Thin walled bulla arising on the skin or oral mucosa 
is the classical lesion of pemphigus with a characteristic 
positive Nikolsky’s sign, which is also found in 
toxic epidermal necrolysis (TEN) and scalded skin 
syndrome (both acute lesions), as well as in mucous 
membrane pemphigoid.8 The lesions of pemphigus 
should be differentiated from acute viral infections and 
other lesions seen in immunocompromised patients 
such as atypical ulcers lasting for weeks to months if 
undiagnosed or untreated. 
The diagnosis of such clinically suspicious lesions of 
pemphigus can be best confirmed with a combination 
of a thorough patient history, laboratory investigations 
and histopathological features.9 A fresh vesicle or the 
edge of a blister less than 24 hours old, accompanied by 
adjacent normal skin or mucosa, should be obtained for 
histopathology or direct immunofluorescence (DIF).9  
The key histological feature of pemphigus is an intra-
epidermal split with the loss of adhesion and separation of 
normal appearing keratinocytes referred to as acantholysis. 
In PV, the histology shows suprabasilar split with 
acantholysis of keratinocytes, which helps to distinguish 
from other conditions such as mucous membrane 
pemphigoid, bullous lichen planus and chronic ulcerative 
stomatitis. In PV, DIF will be positive for intercellular 
IgG deposition and C3 antibodies involving the entire 
perilesional skin or mucosa.9
In the present case, the patient had no history 
of immunocompromising disorders and was not 
taking any drugs to treat any such disorders. Indirect 
immunofluorescence has a lower sensitivity than DIF, but it 
may be useful in cases where it is difficult to obtain a biopsy.5 
The management of all variants of pemphigus is done in two 
phases: the loading phase to control the disease, followed 
by the maintenance phase to induce disease remission.10 
Corticosteroids are considered as the gold standard in the 
management of all variants of pemphigus, and were first 
used by Thorn et al.,11 and further popularized by Costello 
et al.,12 later in that decade, and Lever et al.,13 
With the use of these drugs a drastic decrease in the 
mortality rate associated with PV occurred, estimated 
to be 5 to 15%.14 Topical agents are preferred over 
systemic drugs except during acute exacerbations. 
Topical corticosteroids for a short duration are safe, but 
prolonged use can lead to side effects such as secondary 
candidiasis and atrophy of the oral mucosa.15 Systemic 
corticosteroids are recommended during acute conditions 
and for persistent erosions, at high doses (prednisolone 
30-80mg/day) for a short duration (2-3 weeks), known 
as pulse therapy.16  However, such regimens are also not 
free of side effects. Early diagnosis requires lower doses of 
steroids for shorter periods to control the condition.
Pulse therapy is defined as discontinuous or inter-
mittent intravenous infusions of very high doses of drugs 
over a short time. The concept of pulse therapy was first 
introduced in 1969 by Kauntz et al.17
In India, Dr. JS Pasricha et al.18 was the first to use pulse 
therapy for the management of Reiter’s diseases in 1984. 
Pulse therapy has been widely used in the treatment of 
various immunological related disorders. The drugs used in 
pulse therapy include corticosteroids, immunosuppressive 
drugs, antifungals and antibiotics.15 To overcome or 
minimize these limitations without compromising efficacy, 
the concept of oral minipulse (OMP) therapy was designed. 
In the form of OMP therapy, corticosteroids have shown 
efficacy with few and acceptable side effects.19
Early diagnosis with initial daily doses of prednisone 
equivalent to 0.5 to 2.0mg/kg is recommended to control the 
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condition, as well to prevent serious fatal complications.20 
In the present case oral prednisolone 30 mg/day for four 
days along with a multi-vitamin and topical analgesic were 
prescribed on first visit, which resulted in a 50% reduction 
in symptoms with partial healing of lesions. 
The dose of prednisolone was tapered to 20mg/day for the 
next four days, resulting in a 20% reduction in symptoms 
compared to the first follow-up and further reduction in 
the lesions. The prednisolone dose was further tapered to 
10mg/day for following four days. On the third follow-
up, symptoms were completely reduced. The prednisolone 
dose was furthered tapered to 5mg/day for the next three 
days. On final visit, complete regressions of  lesions were 
noticed. The patient was further followed for one year, and 
no recurrence of lesions or any complications were noted. 
CONCLUSION.
Pulse therapy is a promising treatment modality for life 
threatening auto immune disorders. It has been proved 
successful for the treatment of PV without any or with 
acceptable side effects only. The present case illustrates 
that OMP therapy is an appropriate treatment modality to 
manage pemphigus lesions. The advantages of OMP over 
conventional therapy are its convenient dosage schedule, 
efficacy, minimal or acceptable side-effects without any 
complications. Hence, OMP therapy can be employed as a 
routine treatment modality for PV as it offers a non-invasive 
treatment mode that yields significant improvements in the 
clinical condition of patient. However, long term follow up 
is mandatory to compare the incidence of malignancy in 
patients receiving pulse doses of immunosuppressive drugs. 
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